NEW YORK (GenomeWeb) – Qiagen reported after the close of the market Tuesday that its first quarter sales increased 4 percent year over year with growth across all regions and customer classes.

The firm reported total sales of $317.1 million for the three months ended March 31, up from $303.6 million. On an adjusted basis, its sales for the quarter were up 5 percent to $317.4 million at constant exchange rates. It beat the consensus Wall Street estimate of $316.9 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.